www.163.com
INSIGHT...
Aug 30, 2024 · INSIGHT 2研究是首个完整报道MET-TKI联合第三代EGFR-TKI治疗MET介导的奥希替尼耐药患者的II期试验，这一联合方案展示出良好的疗效和可控的安全性，由于治疗相关不良事件导致的停药率低。
insight研究
Searching…
Web results
pubmed.ncbi.nlm.nih.gov
INSIGHT 2: a phase II study of tepotinib plus osimertinib in
Dec 21, 2021 · INSIGHT 2 is an ongoing study that is designed to learn about the effects and safety of tepotinib combined with osimertinib, in patients with lung cancer that has stopped responding to osimertinib becau...
www.thelancet.com
Tepotinib plus osimertinib in patients with - The Lancet
In the INSIGHT 2 study, the combination of tepotinib plus osimertinib showed an objective response rate of 50·0% in patients with EGFR -mutated NSCLC and MET amplification as a resistance mechanism to first-line osimertinib.
www.dxy.cn
吴一龙教授：基于INSIGHT研究结果......
Jan 19, 2020 · 由广东省人民医院吴一龙教授牵头进行的INSIGHT研究在EGFR TKI耐药后MET变异的NSCLC患者中，探索了Tepotinib联合吉非替尼的疗效和安全性，初步的研究结果显示出有前景的疗效，最新的研究结果也在2019年的世界肺癌大会上公布。
cardiology.medsci.cn
AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET...
Apr 11, 2022 · 近期在AACR2022会议上，来自马来亚大学医学院等机构的专家联合报告了INSIGHT试验的最终分析结果。
zhuanlan.zhihu.com
医学洞见(Insight)怎么写? - 知乎
Jan 25, 2021 · “Insight is a statement that typically captures a ‘not yet obvious’ driver of behavior that could impact strategy. This information will help us to enhance our plans and strategies to enable us to bring...
github.com
GitHub - hustzhangwenfeng/insight-researcher: 基于GPT的自主AI ...
基于AI Agent实现了一个自主科研的小工具🌿insight-researcher🌿，可根据用户的研究任务，一键生成万字长文报告，并且报告中引用的数据实时、可溯源，适合写行业研究报告、科研综述等。
www.jto.org
MO01.48 INSIGHT 2: Tepotinib - Journal of Thoracic Oncology
INSIGHT 2 is a global, open-label, Phase II trial of tepotinib + osimertinib in patients with advanced EGFR-mutant NSCLC. Following a protocol amendment in April 2020, the study is enrolling patients with acquired res...
www.annalsofoncology.org
INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR ...
INSIGHT 2 (NCT03940703) is a global single-arm, open-label, phase II trial of tepotinib in patients with advanced (stage IIIB/IV) NSCLC with resistance to 1 st –3 rd generation EGFR TKIs driven by METamp.
www.cancer361.com
肝癌首个靶向药物索拉非尼临床数据以及不良反应-INSIGHT研究
INSIGHT研究是一项针对HCC患者的国际 (德国/奥地利)非干预上市后监测研究。 INSIGHT研究旨在评估患者的特点，以及 索拉非尼 在现实治疗条件下的疗效和安全性。